Urology
Volume 74, Issue 1 , Pages 15-21 , July 2009

Ejaculatory Dysfunction and Its Association With Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia and BPH Treatment

  • Wayne J.G. Hellstrom

      Affiliations

    • Tulane University Health Sciences Center, New Orleans, Louisiana
    • Corresponding Author InformationReprint requests: Wayne J. G. Hellstrom, M.D., F.A.C.S., Department of Urology, Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-42, New Orleans, LA 70112
    • ,
  • François Giuliano

      Affiliations

    • AP-HP, Raymond Poincaré Hospital, Garches, France
    • ,
  • Raymond C. Rosen

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts

Received 8 April 2008 ,Accepted 25 June 2008.

References 

  1. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–649
  2. Coolen LM, Allard J, Truitt WA, et al. Central regulation of ejaculation. Physiol Behav. 2004;83:203–215
  3. Holstege G, Georgiadis JR, Paans AM, et al. Brain activation during human male ejaculation. J Neurosci. 2003;23:9185–9193
  4. Giuliano F, Clement P. Physiology of ejaculation: Emphasis on serotonergic control. Eur Urol. 2005;48:408–417
  5. Marson L, McKenna KE. A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes. Exp Brain Res. 1992;88:313–320
  6. Hull EM, Eaton RC, Markowski VP, et al. Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: Implications for copulation. Life Sci. 1992;51:1705–1713
  7. Waldinger MD, Berendsen HH, Blok BF, et al. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: The involvement of the serotonergic system. Behav Brain Res. 1998;92:111–118
  8. Peeters M, Giuliano F. Central neurophysiology and dopaminergic control of ejaculation. Neurosci Biobehav Res. 2008;32:438–453
  9. Olivier B, Chan JS, Pattij T, et al. Psychopharmacology of male rat sexual behavior: Modeling human sexual dysfunctions?. Int J Impot Res. 2006;18(suppl 1):S14–S23
  10. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol. 2002;168:2359–2367
  11. Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50-78 years old: Prevalence, concern, and relation to sexual activity. Urology. 2001;57:763–768
  12. Blanker MH, Bohnen AM, Groeneveld FP, et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: A community-based study. J Am Geriatr Soc. 2001;49:436–442
  13. Chung WS, Nehra A, Jacobson DJ, et al. Lower urinary tract symptoms and sexual dysfunction in community-dwelling men. Mayo Clin Proc. 2004;79:745–749
  14. Rosen R, Althof S, Catania J, et al. Lower urinary tract symptoms and sexual dysfunction: Epidemiological findings from the Men's Sexual Health Population Survey. (abstract) J Urol. 2005;173:6
  15. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: A survey of ageing men from five Asian countries. BJU Int. 2005;96:1339–1354
  16. Frankel SJ, Donovan JL, Peters TI, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 1998;51:677–685
  17. Tubaro A, Polito M, Giambroni L, et al. Sexual function in patients with LUTS suggestive of BPH. Eur Urol. 2001;40(suppl 1):19–22
  18. Vallancien G, Emberton M, Harving N, et al. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169:2257–2261
  19. Roehrborn CG, Nuckolls JG, Wei JT, et al. The Benign Prostatic Hyperplasia Registry and Patient survey: Study design, methods and patient baseline characteristics. BJU Int. 2007;100:813–819
  20. Rosen R, McVary K, Nuckolls J, et al. Lower urinary tract symptoms severity and International Prostate Symptom Score bother question correlate with measures of erectile and ejaculatory dysfunction in benign prostatic hyperplasia. (abstract) J Urol. 2005;173(suppl):337
  21. McVary KT. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol. 2005;47:838–845
  22. Rosen R, Carson C, Giuliano F. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824–837
  23. Fourcade RO, Theret N, Taieb C. Sexual function and opinion of patients treated for the first time for LUTS/BPH. (abstract) Eur Urol Suppl. 2008;7:169
  24. AUA Practice Guidelines Committee for the American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003)—Chapter 3: Results of the treatment outcomes analyses. Linthincum, MD: American Urological Association; 2003;
  25. Brookes ST, Donovan JL, Peters TJ, et al. Sexual dysfunction in men after treatment for lower urinary tract symptoms: Evidence from randomised controlled trial. BMJ. 2002;324:1059–1061
  26. Muntener M, Aellig S, Kuettel R, et al. Sexual function after transurethral resection of the prostate (TURP): Results of an independent prospective multicentre assessment of outcome. Eur Urol. 2007;52:510–515
  27. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92:257–261
  28. Uroxatral (alfuzosin HCl) extended release tablets. Bridgewater, NJ: Sanofi-Aventis U.S; 2006;[prescribing information]
  29. Van Kerrebroeck P, Jardin A, van Cangh P, et al. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: Open-label extension study. Eur Urol. 2002;41:54–61
  30. Elhilali M, Emberton M, Matzkin H, et al. Long-term efficacy and safety of alfuzosin 10 mg once daily: A 2-year experience in “real-life” practice. BJU Int. 2006;97:513–519
  31. van Moorselaar RJ, Hartung R, Emberton M, et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005;95:603–608
  32. Rosen R, Catania J, Pollack L, et al. Male sexual health questionnaire (MSHQ): Scale development and psychometric validation. Urology. 2004;64:777–782
  33. Chung B, Lee J, Kim C, et al. Sexuality and the Management of BPH with Alfuzosin (SAMBA) trial. (abstract) Eur Urol Suppl. 2008;7:172
  34. AUA Practice Guidelines Committee for the American Urological Association. AUA guideline on management of benign prostatic hyperplasia (2003)—Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170:530–547
  35. Cardura XL (doxazosin mesylate). New York: Pfizer Inc; 2006;[prescribing information]
  36. Hytrin (terazosin HCl) capsules. North Chicago, IL: Abbott Laboratories; 2001;[prescribing information]
  37. Flomax (tamsulosin hydrochloride). Rigdefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2006;[prescribing information]
  38. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001;57:466–470
  39. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176:1529–1533
  40. Hisasue S, Furuya R, Itoh N, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006;13:1311–1316
  41. Giuliano F, Bernabe J, Droupy S, et al. A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int. 2004;93:605–608
  42. Giuliano FA, Clement P, Denys P, et al. Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats. BJU Int. 2006;98:876–879
  43. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–1024
  44. Kobayashi K, Masumori N, Kato R, et al. Orgasm preserved regardless of ejaculatory dysfunction with selective alpha-1A-blocker administration. (abstract) Eur Urol Suppl. 2008;7:186
  45. Proscar (finasteride) tablets. Whitehouse Station, NJ: Merck & Company, Inc; 2007;[prescribing information]
  46. Avodart (dutasteride) soft gelatin capsules. Research Triangle Park, NC: GlaxoSmithKline; 2007;[prescribing information]
  47. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–441
  48. Rosen RC, Seftel AD, Wei JT, et al. Effect of benign prostatic hyperplasia management on ejaculatory function: Longitudinal data from the BPH Registry & Patient Survey. (abstract) J Urol. 2007;177(suppl 4):315

PII: S0090-4295(08)00841-8

doi: 10.1016/j.urology.2008.06.048

Urology
Volume 74, Issue 1 , Pages 15-21 , July 2009

Article Tools

* Image Usage & Resolution